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Fibrosis
Fibrosis is defined as the accumulation of extracellular matrix
leading to structural and functional alterations of several
organs such as lung, heart, kidney, pancreas, liver.
Causes of kidney fibrosis
diabetes, hypertension, infection, inflammation of renal blood vessels
and glomeruli, kidney stones, cysts, genetic mutations.
Kidney Fibrosis
is a common feature of Chronic Kidney Diseases [CKD] (which affect
10-12% of the population) and is characterized by progressive loss of
kidney function and relentless accumulation and deposition of ECM
is considered to be an irreversible process that leads to end-stage
renal failure and requires expensive and life-long treatments with
dialysis or transplantation
is increasing at a rate of approximately 7% per year among the world
population
Why do organs in the body 
develop fibrosis?
Wynn T.A., JCI, 2007
A wound-healing response 
that has gone out of control
45% of all the deaths in the developed world can be 
attributed to some form of fibroproliferative disease
The Unilateral Ureteral Obstruction (UUO) 
model of kidney fibrosis
•in vivo model
•encompasses many aspects of other 
models of kidney fibrosis
•there are features that occur 
within 1 week
•there is evidence that animal models 
with UUO are reflective of the molecular 
changes in human situations
•leaves one kidney intact
•mimics in a short time a situation 
that can take years in humans
Proteomic analysis
Sham operated 2d UUO 2d 
Sham operated 8d UUO 8d 
UUO  2d UUO 8d 
Kypreou K. et al., Proteomics, 2008
Proteomic Approach
Classical 2DE
1st dimension: IEF (pI 3-10)
2nd dimension: Gel electrophoresis
PD Quest Image processing Software
Spot excision and tryptic digestion
MALDI-TOF/TOF-MS
MASCOT Software for protein identification
Proteins altered in all repeats of the experiment (3 different
animals from each group) were selected for further evaluation
Venn diagram of identified proteins
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Calreticulin is a 
multifunctional protein
• First isolated in 1974 as a
high-affinity Ca2+-binding
protein of the ER
There is no correlation with fibrotic processes yet !
TRENDS in Cell Biology, Vol.11, 2001
Confirmation of Calreticulin upregulation
in fibrotic samples
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Quantification of calreticulin
protein expression
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Quantification of calreticulin
mRNA expression
Kypreou K. et al., Proteomics, 2008
Why is Calreticulin upregulated
in kidney fibrosis?
 Which is the mechanism of Calreticulin 
upregulation?
 What is the role of Calreticulin in fibrosis?
1. WHICH IS THE MECHANISM OF 
CALRETICULIN UPREGULATION?
Transforming Growth Factor-β (TGF-β) induces fibroblasts 
to synthesize ECM and has long been considered as a central 
mediator of the fibrotic response
Transforming Growth Factor-β (TGF-β)
induces HK-2 cells to produce Calreticulin
Sham operated Ligated 2 days Ligated 8 days
Kypreou K. et al., Proteomics, 2008
TGF-β-mediated Calreticulin induction is 
accompanied by Epithelial to Mesenchymal 
Transition in HK-2 cells
-TGF-β
+TGF-β
a smooth muscle 
actin x 40
-
-TGF-β
+TGF-β
Epithelial to Mesenchymal Transition
TGF-β induces Calreticulin mRNA expression 
in HK-2 cells
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Quantification of Calreticulin mRNA 
expression by Real-time RT-PCR
What is upstream of this induction?

Bioinformatics analysis 
on Calreticulin promoter
 www.genomatix.de: Gene2Promoter
 4 organisms:
 Promoter sequence: 2000bp upstream and 1000bp 
downstream the TSS
Calreticulin promoter sequence contains TF binding 
sites that act downstream of the TGF-β signaling  
calreticulin
YY1
E2F4
Sp1
Smad
TATA
Myc
C/EBP
- 1800bp - 300bp
Cloning of the human Calreticulin
promoter sequence
CALR
-1800
exon1
+1-1000 -500-1500 +86
TATA
-27
Sp1
-71
Sp1
-251
Sp1
-305
Smad
-291
Smad
-691
Smad
-706
Smad
-897
Smad
-1744
Myc
-223
Myc
-282
Myc
-1080
C/EBP
-926
E2F4
YY1
-175
E2F
-318
pGL3-Basic
M
C
S
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BglII
Luc
TGF-β induces Calreticulin promoter activity 
in HK-2 cells
TGF-β regulates Calreticulin at the level of 
transcriptional activation
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Calreticulin promoter activity
upon TGF-β stimulation in HK-2 cells
Calreticulin promoter is regulated by transcription 
factors E2F4 and p107
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Calreticulin promoter activity 
upon TF stimulation in HEK293 cells
E2F4 and p107 act downstream the TGF-β signaling pathway
E2F4 has potential binding sites on Calreticulin promoter
E2F4 and its cytoplasmic binding partner p107 are cell cycle regulators
Calreticulin promoter deletion constructs
CALR
-1800
exon1
+1-1000 -500-1500 +86
TATA
-27
Sp1
-71
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Smad
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Smad
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Smad
-897
Smad
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Myc
-282
Myc
-1080
C/EBP
-926
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-1215 +86
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TATA
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YY1
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E2F4
C/EBP
Calreticulin promoter includes 
activator and repressor elements
 The region from -1215 to -1800 contains transcriptional activator element(s)
 The region from -226 to -522 contains transcriptional repressor element(s)
 The fragment -226/+86 harbors the basal/core promoter sequence whose
activity is altered by upstream activator and repressor elements
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Deletion constructs 
activity in HK2 cells
Calreticulin promoter includes 
activator and repressor elements
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Deletion constructs 
activity in HK2 cells
CALRTATABasal promoterRepressorActivator
-1800 -1215 -522 -226 +1
transcription
(+)
(-)
Calreticulin gene regulation is even 
more complicated…
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Deletion constructs activity in 
HK-2 cells
…representing the multiplicity of Calreticulin functions
Which is the mechanism of Calreticulin 
upregulation in fibrosis?
TGF-β is likely to play a role. 
Other factors should also play a role, taking into
consideration the complex nature of both fibrosis and
Calreticulin regulation.
More signaling pathways and transcription factors that
upregulate Calreticulin gene expression need to be studied, and
corresponded to specific regulatory elements on Calreticulin
promoter.
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